Efficacy and Safety of Enzalutamide (Xtandi) Monotherapy in Hormone-Naive Prostate Cancer (HNPC)

Xtandi is often referred to as a “super bicalutamide (Casodex).” Casodex functions as a androgen blockade, which deters testosterone from being able to interact with the prostate cancer cell and feed the growth of the cancer. There are some oncologists in the United States and the standard hormone treatment in Europe often utilizes Casodex as [...]

Xtandi Today & Tomorrow

Medivation, the pharmaceutical company that owns Xtandi (formerly known as MDV-3100), the new androgen receptor antagonist to treat castrate resistant advanced prostate cancer has a number of active clinical trials, despite the fact that it has already been approved for use. The current FDA approval is specific; it has been approved for men who are [...]

Combined Androgen Blockade (ADT2) with Bicalutamide (Casodex) For Advanced Prostate Cancer Provides Increased Survival Time

One of the first treatments used when diagnosed with advanced or recurrent prostate cancer is hormone therapy. Hormone therapy (androgen blockade) is a systematic treatment, or it treats the cancer through the entire body. Prostate cancer that is believed to be in the gland is treated with a localized, focused treatment of the actual gland [...]

Men With Low Testosterone Die Sooner – What Is The Implications For Men On An Androgen Blockade?

"All-cause mortality” or death by all causes has been shown to increase in men who have deficiencies of testosterone. A new study, conducted in Germany, recently came to this conclusion. In this study, The Study of Health in Pomerania (SHIP), the researchers looked at death rates from any cause in almost 2,000 men aged 20 [...]